🔗 Share this article

The first new treatments for gonorrhoea in decades are being described as a "significant breakthrough" in the fight against drug-resistant strains of the infection, according to researchers.

An International Challenge

Gonorrhoea infections are increasing globally, with estimates suggesting in excess of 82 million infections per year. Particularly high rates are seen in Africa and nations within the WHO's designated area, which spans from China and Mongolia to New Zealand. Within England, cases have reached a record high, while figures across Europe in 2023 were triple the level compared to the rates from 2014.

“The approval of fresh medications for gonorrhoea is an important and timely advancement in the context of rising global incidence, escalating drug resistance and the very limited treatment choices presently on offer.”

Public health authorities are deeply concerned about the rise in antibiotic-resistant strains. The global health body has designated it as a "critical concern". A tracking program showed that the effectiveness of key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Recent Treatment Options Receive Clearance

One new antibiotic, alternatively called a brand name, was cleared by the American regulatory agency in mid-December for use against gonorrhoea. This infection can lead to major issues, including the inability to conceive. Researchers believe that focused deployment of this new drug will help delay the development of resistance.

Another new antibiotic, developed by the pharmaceutical company GlaxoSmithKline, also received approval in concurrent days. This treatment, which is additionally indicated for urinary tract infections, was demonstrated in studies to be able to combat drug-resistant strains of the gonorrhoea bacteria.

An Innovative Development Model

This new treatment emerged from a innovative non-profit model for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company Innoviva to develop it.

“This milestone marks a significant shift in the therapy of superbug gonorrhoea, which until now has been staying ahead of antibiotic development.”

Clinical Trial Data and Worldwide Availability

Based on data published in a prominent scientific publication, zoliflodacin cured more than 90% of uncomplicated infections. This puts it on an similar efficacy with the existing first-line therapy, which uses a dual-drug approach. The study involved hundreds of participants from several countries including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its development partnership, the non-profit has the rights to register and commercialise the drug in a wide range of low-income and middle-income countries.

Doctors treating patients have shared positive views. Access to a one-pill regimen like this is seen as a "critical tool" for managing the epidemic. This is deemed vital to alleviate the strain of the infection for patients and to stop the proliferation of extremely resistant gonorrhoea globally.